Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| MFNS | Mometasone furoate nasal spray (MFNS) 50 mcg nasal spray device. The dose was as follows: * 5 to 11 years: one spray per nostril once daily (100 mcg/day as MF) in the morning for 2 weeks. * 12 to 15 years: 2 sprays per nostril once daily (200 mcg/day as MF) in the morning for 2 weeks. | None | None | 0 | 220 | 24 | 220 | View |
| Placebo | Placebo MFNS. Administration was as follows: * 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks. * 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks. | None | None | 0 | 113 | 19 | 113 | View |